Protective Host Immunity Against Pulmonary Cryptoccoccosis

宿主对肺隐球菌病的保护性免疫

基本信息

  • 批准号:
    7587322
  • 负责人:
  • 金额:
    $ 34.7万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2007
  • 资助国家:
    美国
  • 起止时间:
    2007-03-01 至 2012-02-28
  • 项目状态:
    已结题

项目摘要

DESCRIPTION (provided by applicant): Cryptococcus neoformans infections among HIV-infected individuals in the United States occurs at a prevalence rate of 5-10% and is a leading mycological cause of morbidity and mortality among AIDS patients. Studies have suggested that cell-mediated immunity (CMI) by T helper (Th) 1-type CD4+ T cells is the predominant host defense mechanism against C. neoformans infections. However, the detailed immunological response that would elicit protection against cryptococcal relapse or reinfection is yet to be defined. In our preliminary studies, we have shown that an experimental pulmonary infection with an interferon gamma (IFN-g)-producing C. neoformans strain in mice results in the induction of Th1-type CMI responses and resolution of the acute infection. Furthermore, we have for the first time demonstrated that prior challenge with an IFN-g-producing C. neoformans strain results in complete (100%) protection against a second pulmonary challenge with a pathogenic C. neoformans strain. Based on these results, we hypothesize that C. neoformans strains engineered to produce IFN-g can be used to determine the mechanism(s) involved in protective host immunity against pathogenic pulmonary C. neoformans infections. Therefore, we propose to use this model system to analyze protective anti-cryptococcal host immune responses using the following "Specific Aims": (1) To characterize the impact of local cryptococcal IFN-g production on the induction of host immunity against pulmonary cryptococcosis. (2) To determine the immune mechanism(s) that is responsible for resistance against re-infection with a pathogenic C. neoformans strain. (3) To evaluate the local pathology and cellular composition of the inflammatory response in mice resistant and susceptible to experimental pulmonary cryptococcosis. (4) To determine if the route of challenge with the IFN-g producing C. neoformans strain influences the development of protective immunity against pulmonary or disseminated C. neoformans infections. Cryptococcus neoformans is an opportunistic fungus that may cause life-threatening infections of the brain in individuals with suppressed immune systems. I am proposing to perform studies to define the parameters of which protective immune responses can be generated against C. neoformans infections. My expectation is that these studies will lead to the development of therapies and/or vaccines to treat or prevent fungal infections in immune compromised individuals.
描述(由申请方提供):在美国,HIV感染者中的新型隐球菌感染的患病率为5-10%,是AIDS患者发病和死亡的主要真菌原因。研究表明,辅助性T细胞(Th)1型CD 4 + T细胞介导的细胞免疫(CMI)是宿主抵抗C.新型感染。然而,详细的免疫反应,将引起对隐球菌复发或再感染的保护尚未确定。在我们的初步研究中,我们已经表明,实验性肺部感染与干扰素γ(IFN-g)产生的C。在小鼠中的新形式毒株的感染导致诱导Th 1型CMI应答和急性感染的消退。此外,我们首次证明了先前用产生IFN-g的C.新型梭菌菌株导致完全(100%)保护免受致病性梭菌的第二次肺攻击。neoformans菌株。基于这些结果,我们假设C。经工程改造以产生IFN-γ的新生菌菌株可用于确定保护性宿主免疫抵抗致病性肺念珠菌的机制。新型感染。因此,我们建议使用该模型系统来分析保护性抗隐球菌宿主免疫应答,具有以下“特定目的”:(1)表征局部隐球菌IFN-g产生对诱导抗肺隐球菌病的宿主免疫的影响。(2)确定抵抗致病性C. neoformans菌株。(3)评价实验性肺隐球菌病耐药和易感小鼠炎症反应的局部病理学和细胞组成。(4)为确定IFN-γ产生菌的攻毒途径是否可行。新型念珠菌株影响对肺部或播散性念珠菌的保护性免疫的发展。新型感染。新型隐球菌是一种机会性真菌,可能导致免疫系统受抑制的个体发生危及生命的脑部感染。我建议进行研究,以确定可以产生针对C的保护性免疫应答的参数。新型感染。我的期望是,这些研究将导致开发治疗或预防免疫受损个体真菌感染的疗法和/或疫苗。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Floyd L. Wormley其他文献

Identification of two anti-emCandida/em antibodies associated with the survival of patients with candidemia
鉴定两种与念珠菌血症患者存活相关的抗 emCandida/em 抗体
  • DOI:
    10.1128/mbio.02769-23
  • 发表时间:
    2023-12-11
  • 期刊:
  • 影响因子:
    4.700
  • 作者:
    Carla Bromuro;Brunella Posteraro;Rita Murri;Massimo Fantoni;Mario Tumbarello;Maurizio Sanguinetti;Rosanna Dattilo;Roberto Cauda;Antonio Cassone;Antonella Torosantucci;Floyd L. Wormley
  • 通讯作者:
    Floyd L. Wormley
Inhibition of host 5-lipoxygenase reduces overexuberant inflammatory responses and mortality associated with emCryptococcus/em meningoencephalitis
抑制宿主 5-脂氧合酶可减少与隐球菌性脑膜脑炎相关的过度炎症反应和死亡率
  • DOI:
    10.1128/mbio.01483-24
  • 发表时间:
    2024-08-20
  • 期刊:
  • 影响因子:
    4.700
  • 作者:
    Natalia Castro-Lopez;Althea Campuzano;Elysa Mdalel;Difernando Vanegas;Ashok Chaturvedi;Phung Nguyen;Mark Pulse;Astrid E. Cardona;Floyd L. Wormley
  • 通讯作者:
    Floyd L. Wormley
Unraveling the cryptic functions of mitogen-activated protein kinases Cpk2 and Mpk2 in emCryptococcus neoformans/em
解开新型隐球菌中丝裂原活化蛋白激酶 Cpk2 和 Mpk2 的神秘功能
  • DOI:
    10.1128/mbio.01156-24
  • 发表时间:
    2024-06-04
  • 期刊:
  • 影响因子:
    4.700
  • 作者:
    Yu-Byeong ­Jang;Jin-Young Kim;Yong-Sun Bahn;Floyd L. Wormley
  • 通讯作者:
    Floyd L. Wormley

Floyd L. Wormley的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Floyd L. Wormley', 18)}}的其他基金

5-Lipoxygenase Inhibition as a Therapy to Prevent Cryptococcus-related IRIS
5-脂氧合酶抑制作为预防隐球菌相关 IRIS 的疗法
  • 批准号:
    10358634
  • 财政年份:
    2021
  • 资助金额:
    $ 34.7万
  • 项目类别:
5-Lipoxygenase Inhibition as a Therapy to Prevent Cryptococcus-related IRIS
5-脂氧合酶抑制作为预防隐球菌相关 IRIS 的疗法
  • 批准号:
    10256128
  • 财政年份:
    2021
  • 资助金额:
    $ 34.7万
  • 项目类别:
Induction of Protection Against Cryptococcus neoformans in Immune Deficient Hosts
在免疫缺陷宿主中诱导针对新型隐球菌的保护
  • 批准号:
    8499245
  • 财政年份:
    2012
  • 资助金额:
    $ 34.7万
  • 项目类别:
Induction of Protection Against Cryptococcus neoformans in Immune Deficient Hosts
在免疫缺陷宿主中诱导针对新型隐球菌的保护
  • 批准号:
    8414616
  • 财政年份:
    2012
  • 资助金额:
    $ 34.7万
  • 项目类别:
Identification of C. neoformans proteins that induce protective immunity.
诱导保护性免疫的新型隐球菌蛋白的鉴定。
  • 批准号:
    7990317
  • 财政年份:
    2010
  • 资助金额:
    $ 34.7万
  • 项目类别:
Identification of C. neoformans proteins that induce protective immunity.
诱导保护性免疫的新型隐球菌蛋白的鉴定。
  • 批准号:
    8067135
  • 财政年份:
    2010
  • 资助金额:
    $ 34.7万
  • 项目类别:
Protective Host Immunity Against Pulmonary Cryptoccoccosis
宿主对肺隐球菌病的保护性免疫
  • 批准号:
    7775100
  • 财政年份:
    2007
  • 资助金额:
    $ 34.7万
  • 项目类别:
Protective Host Immunity Against Pulmonary Cryptococcosis
宿主对肺隐球菌病的保护性免疫
  • 批准号:
    9214307
  • 财政年份:
    2007
  • 资助金额:
    $ 34.7万
  • 项目类别:
Protective Host Immunity Against Pulmonary Cryptoccoccosis
宿主对肺隐球菌病的保护性免疫
  • 批准号:
    8019452
  • 财政年份:
    2007
  • 资助金额:
    $ 34.7万
  • 项目类别:
Protective Host Immunity Against Pulmonary Cryptoccoccosis
宿主对肺隐球菌病的保护性免疫
  • 批准号:
    7365221
  • 财政年份:
    2007
  • 资助金额:
    $ 34.7万
  • 项目类别:

相似海外基金

Transcriptional assessment of haematopoietic differentiation to risk-stratify acute lymphoblastic leukaemia
造血分化的转录评估对急性淋巴细胞白血病的风险分层
  • 批准号:
    MR/Y009568/1
  • 财政年份:
    2024
  • 资助金额:
    $ 34.7万
  • 项目类别:
    Fellowship
Combining two unique AI platforms for the discovery of novel genetic therapeutic targets & preclinical validation of synthetic biomolecules to treat Acute myeloid leukaemia (AML).
结合两个独特的人工智能平台来发现新的基因治疗靶点
  • 批准号:
    10090332
  • 财政年份:
    2024
  • 资助金额:
    $ 34.7万
  • 项目类别:
    Collaborative R&D
Acute senescence: a novel host defence counteracting typhoidal Salmonella
急性衰老:对抗伤寒沙门氏菌的新型宿主防御
  • 批准号:
    MR/X02329X/1
  • 财政年份:
    2024
  • 资助金额:
    $ 34.7万
  • 项目类别:
    Fellowship
Cellular Neuroinflammation in Acute Brain Injury
急性脑损伤中的细胞神经炎症
  • 批准号:
    MR/X021882/1
  • 财政年份:
    2024
  • 资助金额:
    $ 34.7万
  • 项目类别:
    Research Grant
KAT2A PROTACs targetting the differentiation of blasts and leukemic stem cells for the treatment of Acute Myeloid Leukaemia
KAT2A PROTAC 靶向原始细胞和白血病干细胞的分化,用于治疗急性髓系白血病
  • 批准号:
    MR/X029557/1
  • 财政年份:
    2024
  • 资助金额:
    $ 34.7万
  • 项目类别:
    Research Grant
Combining Mechanistic Modelling with Machine Learning for Diagnosis of Acute Respiratory Distress Syndrome
机械建模与机器学习相结合诊断急性呼吸窘迫综合征
  • 批准号:
    EP/Y003527/1
  • 财政年份:
    2024
  • 资助金额:
    $ 34.7万
  • 项目类别:
    Research Grant
FITEAML: Functional Interrogation of Transposable Elements in Acute Myeloid Leukaemia
FITEAML:急性髓系白血病转座元件的功能研究
  • 批准号:
    EP/Y030338/1
  • 财政年份:
    2024
  • 资助金额:
    $ 34.7万
  • 项目类别:
    Research Grant
STTR Phase I: Non-invasive focused ultrasound treatment to modulate the immune system for acute and chronic kidney rejection
STTR 第一期:非侵入性聚焦超声治疗调节免疫系统以治疗急性和慢性肾排斥
  • 批准号:
    2312694
  • 财政年份:
    2024
  • 资助金额:
    $ 34.7万
  • 项目类别:
    Standard Grant
ロボット支援肝切除術は真に低侵襲なのか?acute phaseに着目して
机器人辅助肝切除术真的是微创吗?
  • 批准号:
    24K19395
  • 财政年份:
    2024
  • 资助金额:
    $ 34.7万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
Acute human gingivitis systems biology
人类急性牙龈炎系统生物学
  • 批准号:
    484000
  • 财政年份:
    2023
  • 资助金额:
    $ 34.7万
  • 项目类别:
    Operating Grants
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了